SCHEMBL21335573

SCHEMBL21335573

CCOc1ccc2cc(C=O)n(CC)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
MAPT P10636 5/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HPGD P15428 3/20 0.42
ACSS2 Q9NR19 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CYP1A2 P05177 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA5A P35218 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
CA5B Q9Y2D0 1/20 0.41
PTGER4 P35408 1/20 0.40
KDM4E B2RXH2 4/20 0.39
HSD17B10 Q99714 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21335565 0.86 NPSR1 (0.59) ALDH1A1MAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL21335672 0.80 MAPT (0.46) ALDH1A1MAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL18247728 0.80 CYP2A6 (0.40) ALDH1A1MAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL18247574 0.78 CCR9 (0.39) ALDH1A1MAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL18258135 0.78 MAPT (0.45) ALDH1A1MAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL18247762 0.77 GPR35 (0.56) ALDH1A1MAPTSMN1; SMN2HPGDACSS2
SCHEMBL4784169 0.76 PTGER4 (0.43) ALDH1A1SMN1; SMN2HPGDCA12CYP1A2
SCHEMBL18247416 0.74 NOD2 (0.49) ALDH1A1MAPTSMN1; SMN2NPSR1HPGD
SCHEMBL20853273 0.72 PTGER4 (0.44) ALDH1A1MAPTSMN1; SMN2NPSR1RXFP1
SCHEMBL15553394 0.71 CYP2A6 (0.41) MAPTPTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407407-B2 Benzoimidazole derivatives as PAD4 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407407-B2 Benzoimidazole derivatives as PAD4 inhibitors PADI4, PADI1, PADI2 ALDH1A1 209/4885MAPT 4738/4885SMN1; SMN2 4198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.